logo

For the Inventor, By the Inventor

Yokohama, Japan

Eiki Shitara

This inventor holds 17 USPTO granted patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Meiji Seika Kaisha, Ltd., Meiji Seika Kabushiki Kaisha, Taisho Pharmaceutical Co., Ltd.. Active years: 1995-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eiki Shitara. Retrieved from https://idiyas.com/inventor/eiki-shitara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 35.3

 

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 83(Granted Patents)


Location History:

  • Kanagawa-ken, JP (1997 - 2009)
  • Yokohama, JP (1995 - 2010)
  • Kanagawa, JP (2012 - 2015)

Company Filing History:

goldMedal8 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents
silverMedal6 out of 32 
 
Meiji Seika Kabushiki Kaisha
 patents
bronzeMedal3 out of 314 
 
Taisho Pharmaceutical Co., Ltd.
 patents
4. 2 out of 107 
 
Meiji Seika Pharma Co., Ltd.
 patents
5. 1 out of 191 
 
Sagami Chemical Research Center
 patents
6. 1 out of 212 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
 patents
7. 1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1995-2015

Loading Chart...
Loading Chart...
Areas of Expertise:
Carbapenem Derivatives
Platelet Aggregation Inhibitors
Macrolide Derivatives
Imidazothiazole Derivatives
Diketone Compounds
Azalide Compounds
Glycosidase Inhibitors
Pyridine Derivatives
Intermediates Production
Quaternary Salt Type
2-Amino-5-Methylpiperidine
Angiotensin II Antagonism
17 patents (USPTO):Explore Patents
1. 9139609 - C-4″ position substituted macrolide derivative (2015-09-22),
2. 8293715 - 10a-Azalide compound crosslinked at 10a- and 12-positions (2012-10-23),
3. 8097708 - 10a-Azalide compound (2012-01-17),
4. 7662841 - Imidazothiazole derivatives and process for producing the same (2010-02-16),
5. 7563901 - Intermediates of 2-substituted carbapenem derivatives and process for production thereof (2009-07-21),
6. 7524951 - Intermediates of 2-substituted carbapenem derivatives and process for production thereof (2009-04-28),
7. 7482445 - Crystalline carbapenem intermediate (2009-01-27),
8. 6908913 - Carbapenem derivatives (2005-06-21),
9. 6852735 - Siastatin B derivatives having a glycosidase inhibitory activity and processes for producing the same (2005-02-08),
10. 6825187 - Carbapenem derivatives of quarternary salt type (2004-11-30),
11. 6610709 - 2-n-substituted or unsubstituted-2-amino-5-methylpiperidine-3,4-diols and processes for the preparation thereof (2003-08-26),
12. 5958981 - .gamma.-diketone compounds with inhibitory activity against platelet (1999-09-28),
13. 5814636 - Compounds with platelet aggregation inhibitor activity (1998-09-29),
14. 5760053 - .gamma.-Diketone compounds with inhibitory activity against platelet (1998-06-02),
15. 5698692 - Compound with platelet aggregation inhibitor activity (1997-12-16),

Title: Eiki Shitara: Innovator in Macrolide Derivatives

Introduction

Eiki Shitara is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of macrolide compounds. With a total of 17 patents to his name, Shitara's work has been instrumental in addressing antibiotic resistance.

Latest Patents

Among his latest patents is the "C-4″ position substituted macrolide derivative." This macrolide compound is effective against erythromycin-resistant bacteria, including resistant pneumococci, streptococci, and mycoplasmas. Another notable patent is the "10a-Azalide compound crosslinked at 10a- and 12-positions." This novel compound is also effective against erythromycin-resistant bacteria, showcasing Shitara's commitment to combating antibiotic resistance.

Career Highlights

Eiki Shitara has worked with notable companies such as Meiji Seika Kaisha, Ltd. and Meiji Seika Kabushiki Kaisha. His experience in these organizations has allowed him to develop innovative solutions in the pharmaceutical industry.

Collaborations

Shitara has collaborated with esteemed colleagues, including Tomoaki Miura and Kiyoaki Katano. Their combined expertise has contributed to the advancement of research in macrolide derivatives.

Conclusion

Eiki Shitara's innovative work in the field of macrolide compounds has made a significant impact on the fight against antibiotic resistance. His contributions continue to influence the pharmaceutical landscape, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…